Post discusses an undervalued psilocybin stock compared to CMPS (Compass Pathways). Key risks include regulatory uncertainty around psychedelic drug approval, early-stage company execution risk, and market sentiment volatility in this emerging sector.

Compass Pathways released new 52-week topline data from their Phase 3 COMP005 trial showing additional benefit from another COMP360 dose in Part C, with extended durability out to 1 year. Key risks include regulatory approval uncertainty for psilocybin-based therapies and clinical trial setbacks.

Author predicts Compass Pathways ($CMPS) will reach $30 per share if it breaks through the $17 resistance level, citing positive after-hours price action. Key risks include whether the stock can maintain momentum through resistance and broader market conditions affecting biotech/mental health treatment companies.

Post appears to reference CMPS (Compass Pathways) with a colloquial expression indicating a bullish position. Key risk is the speculative nature of psychedelic therapy companies with regulatory uncertainty and pre-commercial stage operations.

COMPASS Pathways (CMPS) is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression that has met Phase 3 trial endpoints and received FDA Breakthrough Therapy designation, positioning it as a potential first-to-market regulated psilocybin treatment with significant upside potential if approved and commercially adopted.

COMPASS Pathways (CMPS) is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression, with both Phase 3 trials meeting primary endpoints and FDA Breakthrough Therapy designation positioning it toward NDA approval. Key risks include regulatory approval uncertainty, commercial adoption execution, and competitive threats in the emerging psychedelic therapeutics space.